Objective:To evaluate the safety and efficacy of percutaneous microwave ablation(MWA)combined with simultaneous transarterial chemoembolization(TACE)in patients with hepatocellular carcinoma(HCC)patients with microvas...Objective:To evaluate the safety and efficacy of percutaneous microwave ablation(MWA)combined with simultaneous transarterial chemoembolization(TACE)in patients with hepatocellular carcinoma(HCC)patients with microvascular invasion(MVI)or extrahepatic metastases(EHM).Methods:Between August 2012 and April 2017,101 patients with MVI/EHM of HCC underwent percutaneous MWA combined with simultaneous TACE at our center.The clinical data were collected and analyzed for survival and prognostic factors.Results:The mean follow-up time was 23.6±14.7 months.One patient had grade 3 complications,and the median overall survival was 12.0 months(95%confidence interval 9.7-14.3).Multivariate analysis showed that ChildPugh class,serum alpha-fetoprotein level,and Eastern Cooperative Oncology Group performance status were independent factors of survival.Conclusion:Our results suggest that percutaneous MWA combined with simultaneous TACE is a safe and effective treatment for HCC with MVI/EHM.展开更多
文摘Objective:To evaluate the safety and efficacy of percutaneous microwave ablation(MWA)combined with simultaneous transarterial chemoembolization(TACE)in patients with hepatocellular carcinoma(HCC)patients with microvascular invasion(MVI)or extrahepatic metastases(EHM).Methods:Between August 2012 and April 2017,101 patients with MVI/EHM of HCC underwent percutaneous MWA combined with simultaneous TACE at our center.The clinical data were collected and analyzed for survival and prognostic factors.Results:The mean follow-up time was 23.6±14.7 months.One patient had grade 3 complications,and the median overall survival was 12.0 months(95%confidence interval 9.7-14.3).Multivariate analysis showed that ChildPugh class,serum alpha-fetoprotein level,and Eastern Cooperative Oncology Group performance status were independent factors of survival.Conclusion:Our results suggest that percutaneous MWA combined with simultaneous TACE is a safe and effective treatment for HCC with MVI/EHM.
